In summary, we provide the first demonstration that clinically approved drugs that inhibit PARP1 can selectively target and eliminate cells experiencing a telomere crisis to prevent cell proliferation and immortalisation, suggesting the exciting possibility of novel therapeutic avenues for PARPi in the context of tumours and pre-cancerous lesions exhibiting short dysfunctional telomeres. Here, PARP1 is linked to neoplasm.